These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30746706)

  • 1. Molecular comparison of interval and screen-detected breast cancers.
    Cheasley D; Li N; Rowley SM; Elder K; Mann GB; Loi S; Savas P; Goode DL; Kader T; Zethoven M; Semple T; Fox SB; Pang JM; Byrne D; Devereux L; Nickson C; Procopio P; Lee G; Hughes S; Saunders H; Fujihara KM; Kuykhoven K; Connaughton J; James PA; Gorringe KL; Campbell IG
    J Pathol; 2019 Jun; 248(2):243-252. PubMed ID: 30746706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular subtypes of screen-detected breast cancer.
    Farshid G; Walters D
    Breast Cancer Res Treat; 2018 Nov; 172(1):191-199. PubMed ID: 30046938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Mortality Among Participants of Women's Health Initiative Trials With Screening-Detected Breast Cancers vs Interval Breast Cancers.
    Irvin VL; Zhang Z; Simon MS; Chlebowski RT; Luoh SW; Shadyab AH; Krok-Schoen JL; Tabung FK; Qi L; Stefanick ML; Schedin P; Jindal S
    JAMA Netw Open; 2020 Jun; 3(6):e207227. PubMed ID: 32602908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic landscape of interval and screen detected breast cancer.
    Mills C; Sud A; Everall A; Chubb D; Lawrence SED; Kinnersley B; Cornish AJ; Bentham R; Houlston RS
    NPJ Precis Oncol; 2024 May; 8(1):122. PubMed ID: 38806682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAM50 and Risk of Recurrence Scores for Interval Breast Cancers.
    Puvanesarajah S; Nyante SJ; Kuzmiak CM; Chen M; Tse CK; Sun X; Allott EH; Kirk EL; Carey LA; Perou CM; Olshan AF; Henderson LM; Troester MA
    Cancer Prev Res (Phila); 2018 Jun; 11(6):327-336. PubMed ID: 29622545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of clinical-pathological characteristics between symptomatic and interval breast cancer.
    Meshkat B; Prichard RS; Al-Hilli Z; Bass GA; Quinn C; O'Doherty A; Rothwell J; Geraghty J; Evoy D; McDermott EW
    Breast; 2015 Jun; 24(3):278-82. PubMed ID: 25771080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors and tumor characteristics of interval cancers by mammographic density.
    Holm J; Humphreys K; Li J; Ploner A; Cheddad A; Eriksson M; Törnberg S; Hall P; Czene K
    J Clin Oncol; 2015 Mar; 33(9):1030-7. PubMed ID: 25646195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
    Wang YA; Jian JW; Hung CF; Peng HP; Yang CF; Cheng HS; Yang AS
    BMC Cancer; 2018 Mar; 18(1):315. PubMed ID: 29566657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of germline variants in inflammatory breast cancer.
    Rana HQ; Sacca R; Drogan C; Gutierrez S; Schlosnagle E; Regan MM; Speare V; LaDuca H; Dolinsky J; Garber JE; Overmoyer BA
    Cancer; 2019 Jul; 125(13):2194-2202. PubMed ID: 30933323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysis.
    Phi XA; Houssami N; Hooning MJ; Riedl CC; Leach MO; Sardanelli F; Warner E; Trop I; Saadatmand S; Tilanus-Linthorst MMA; Helbich TH; van den Heuvel ER; de Koning HJ; Obdeijn IM; de Bock GH
    Eur J Cancer; 2017 Nov; 85():31-38. PubMed ID: 28886475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
    Bertucci F; Rypens C; Finetti P; Guille A; Adélaïde J; Monneur A; Carbuccia N; Garnier S; Dirix P; Gonçalves A; Vermeulen P; Debeb BG; Wang X; Dirix L; Ueno NT; Viens P; Cristofanilli M; Chaffanet M; Birnbaum D; Van Laere S
    Mol Oncol; 2020 Mar; 14(3):504-519. PubMed ID: 31854063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Differences between Screen-Detected and Interval Breast Cancers Are Largely Explained by PAM50 Subtypes.
    Li J; Ivansson E; Klevebring D; Tobin NP; Lindström LS; Holm J; Prochazka G; Cristando C; Palmgren J; Törnberg S; Humphreys K; Hartman J; Frisell J; Rantalainen M; Lindberg J; Hall P; Bergh J; Grönberg H; Czene K
    Clin Cancer Res; 2017 May; 23(10):2584-2592. PubMed ID: 27587435
    [No Abstract]   [Full Text] [Related]  

  • 13. Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program.
    Kirsh VA; Chiarelli AM; Edwards SA; O'Malley FP; Shumak RS; Yaffe MJ; Boyd NF
    J Natl Cancer Inst; 2011 Jun; 103(12):942-50. PubMed ID: 21540443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular analysis of PALB2-associated breast cancers.
    Lee JEA; Li N; Rowley SM; Cheasley D; Zethoven M; McInerny S; Gorringe KL; James PA; Campbell IG
    J Pathol; 2018 May; 245(1):53-60. PubMed ID: 29431189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screen-detected breast cancer is associated with better prognosis and survival compared to self-detected/symptomatic cases in a Chilean cohort of female patients.
    Walbaum B; Puschel K; Medina L; Merino T; Camus M; Razmilic D; Navarro ME; Dominguez F; Cordova-Delgado M; Pinto MP; Acevedo F; Sánchez C
    Breast Cancer Res Treat; 2021 Sep; 189(2):561-569. PubMed ID: 34244869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence, Characteristics, and Outcomes of Interval Breast Cancers Compared With Screening-Detected Breast Cancers.
    Niraula S; Biswanger N; Hu P; Lambert P; Decker K
    JAMA Netw Open; 2020 Sep; 3(9):e2018179. PubMed ID: 32975573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using tumor phenotype, histological tumor distribution, and mammographic appearance to explain the survival differences between screen-detected and clinically detected breast cancers.
    Chuang SL; Chen SL; Yu CP; Chang KJ; Yen AM; Chiu SY; Fann JC; Tabár L; Stephen DW; Smith RA; Chen HH
    APMIS; 2014 Aug; 122(8):699-707. PubMed ID: 25046200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammographic and clinical characteristics of different phenotypes of screen-detected and interval breast cancers in a nationwide screening program.
    Baré M; Torà N; Salas D; Sentís M; Ferrer J; Ibáñez J; Zubizarreta R; Sarriugarte G; Barata T; Domingo L; Castells X; Sala M
    Breast Cancer Res Treat; 2015 Nov; 154(2):403-15. PubMed ID: 26531756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast ultrasonography (BU) in the screening protocol for women at hereditary-familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories?
    Cortesi L; Canossi B; Battista R; Pecchi A; Drago A; Dal Molin C; Toss A; De Matteis E; Marchi I; Torricelli P; Cascinu S
    Int J Cancer; 2019 Mar; 144(5):1001-1009. PubMed ID: 30098212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do screen-detected breast cancers have positive margins less often than clinically detected breast cancers?
    de Munck L; Siesling S; Bart J; Menke-Pluijmers MB; Otter R; Willemse PH
    Eur J Cancer Prev; 2013 Sep; 22(5):398-403. PubMed ID: 23492953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.